Logo of pheblackwell Link to Publisher's site
FASEB J. 2020 Aug 11 : 10.1096/fj.202001807.
doi: 10.1096/fj.202001807 [Epub ahead of print]
PMCID: PMC7436914
PMID: 32780893

Rationale for the use of N‐acetylcysteine in both prevention and adjuvant therapy of COVID‐19


COVID‐19 may cause pneumonia, acute respiratory distress syndrome, cardiovascular alterations, and multiple organ failure, which have been ascribed to a cytokine storm, a systemic inflammatory response, and an attack by the immune system. Moreover, an oxidative stress imbalance has been demonstrated to occur in COVID‐19 patients. N‐ Acetyl‐L‐cysteine (NAC) is a precursor of reduced glutathione (GSH). Due to its tolerability, this pleiotropic drug has been proposed not only as a mucolytic agent, but also as a preventive/therapeutic agent in a variety of disorders involving GSH depletion and oxidative stress. At very high doses, NAC is also used as an antidote against paracetamol intoxication. Thiols block the angiotensin‐converting enzyme 2 thereby hampering penetration of SARS‐CoV‐2 into cells. Based on a broad range of antioxidant and anti‐inflammatory mechanisms, which are herein reviewed, the oral administration of NAC is likely to attenuate the risk of developing COVID‐19, as it was previously demonstrated for influenza and influenza‐like illnesses. Moreover, high‐dose intravenous NAC may be expected to play an adjuvant role in the treatment of severe COVID‐19 cases and in the control of its lethal complications, also including pulmonary and cardiovascular adverse events.

Keywords: COVID‐19, glutathione, inflammation, N‐acetyl‐L‐cysteine, oxidative stress


angiotensin‐converting enzyme 2
antioxidant responsive element
chronic obstructive pulmonary diseases
coronavirus disease‐2019
chemokine (C‐X‐C motif) ligand 10
epidermal growth factor receptor
glutamate‐cysteine ligase
glutathione peroxidase
glutathione reductase
reduced glutathione (γ‐glutamylcysteinylglycine)
N‐butanoyl GSH derivative
oxidized glutathione
human immunodeficiency virus
heme oxygenase 1
high‐sensitivity C‐reactive protein
intercellular adhesion molecule‐1
intensive care units
MAPK p38
p38 mitogen‐activated protein kinase
matrix metalloproteinase‐
nuclear factor kappa‐light‐chain‐enhancer of activated B cells
normal human bronchial epithelial cells
nitric oxide
nitric oxide synthase
nuclear factor erythroid 2–related factor 2
NAD(P)H dehydrogenase [quinone]‐1
O 2
superoxide radical anion
hypochlorous acid
hydroxyl radical
protein disulfide isomerase
prostaglandin E‐2
peroxyl radical
reactive oxygen species
respiratory syncytial virus
severe acute respiratory syndrome coronaviruses
coronavirus responsible for COVID‐19
T helper‐1
toll‐like receptor 3/hemagglutinin
toll‐like receptor 4
tumor necrosis factor
inflammasome activator thioredoxin interacting protein


Approximately 15% of coronavirus disease‐2019 (COVID‐19) patients suffer from impairment of gas exchange and pneumonia, and 5% undergo acute respiratory distress syndrome (ARDS), septic shock and/or multiple organ failure that require hospitalization in intensive care units (ICU). 1 ARDS, the leading cause of death in COVID‐19 patients, involves a cytokine storm and a systemic inflammatory response resulting from the release of large amounts of pro‐inflammatory cytokines and chemokines that trigger an attack by the immune system. 2 Besides affecting the respiratory system, COVID‐19 affects other systems, also including the cardiovascular system, and diffuse thrombosis is emerging as an important contributor to adverse outcomes in patients with COVID‐19. Different pathogenic disturbances are involved, such as acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; acute coronary syndrome due to acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; microvascular dysfunction due to diffuse microthrombi or vascular injury; stress‐related cardiomyopathy (Takotsubo syndrome); direct viral cardiomyocyte toxicity and myocarditis. 3 All of these complications reflect inflammatory reactions stimulated by the viral infection.

COVID‐19 is particularly severe in individuals who are at risk either because of old age or of pre‐existing pathological conditions. For instance, in Italy the mean age of patients dying of COVID‐19 as of May 28 was 80 years, and 95.9% of deceased persons had important pre‐existing conditions, such as cardiovascular diseases, cerebrovascular diseases, diabetes, dementia, chronic obstructive pulmonary diseases (COPD), cancer, chronic liver disease, chronic renal failure, respiratory failure, human immunodeficiency virus (HIV) infection, autoimmune diseases, and obesity. Specifically, 14.9% had a single comorbidity, 21.5% had 2 comorbidities, and 59.5% had 3 or more comorbidities, with a mean number of 3.3 comorbidities. 4 Especially in patients below the age of 80, the fatal cases were much more frequent in men, 4 who have lower levels of blood reduced glutathione (GSH). 5 Elderly individuals maintain a chronic low level of inflammation that is associated with oxidative stress and inflammatory cytokine production, a condition that increases the severity of viral infections in this population and that could be attenuated by administration of antioxidants. 6

A significant elevation in blood serum glutathione reductase (GR), resulting from oxidative stress imbalance, was detected in COVID‐19 patients, especially when admitted to ICU. 7 From an accumulation of literature data, an endogenous deficiency in GSH may underlie the serious manifestations and death from COVID‐19. 8 As we will discuss below, N‐acetyl‐L‐cysteine (NAC) is used in a broad range of conditions to restore or protect against GSH depletion and has a wide safety margin. It has been of benefit in treating ARDS from other causes and might limit or prevent lung damage in patients with COVID‐19. The evidence for this proposal is reviewed here.


The angiotensin‐converting enzyme 2 (ACE2) is the functional receptor for severe acute respiratory syndrome (SARS) coronaviruses, responsible for entrance into cells of both SARS‐CoV and SARS‐CoV‐2, the etiological agent of COVID‐19. 9 Therefore, the interaction of viral spike proteins with ACE2 is a critical step in the viral replication cycle. The receptor binding domain of the viral spike proteins and ACE2 has several cysteine residues. Molecular dynamic simulations showed that the binding affinity was significantly impaired when all the disulfide bonds of both ACE2 and SARS‐CoV/CoV‐2 spike proteins were reduced to thiol groups. These findings are consistent with the view that the reduction of disulfides into sulfhydryl groups completely impairs the binding of SARS‐CoV/CoV‐2 spike protein to ACE2 (see Figure 1 ) and provide a molecular basis for the severity of COVID‐19 infection due to oxidative stress. 10 Furthermore, both animal studies and clinical studies suggested that supplementation of NAC, which is known to attenuate the tolerance to nitrates, modifies the function of the renin/angiotensin system in vivo. Such an effect is probably mediated by inhibition of ACE activity. 11 By blocking ACE, NAC may provide protection from the deleterious effects of angiotensin II, a potentially useful activity in SARS‐CoV‐2 infection. 12

An external file that holds a picture, illustration, etc.
Object name is FSB2-9999-na-g001.jpg

Major mechanisms involved in the antioxidant and anti‐inflammatory action of NAC via GSH (modified and updated from Sadowska, 2012 14 ). The blue arrows indicate stimulation of downstream activities or pathways, whereas the T‐shaped symbols indicate inhibition of downstream activities or pathways. See Text for details, references, and meaning of acronyms


Reduced glutathione (GSH) is a major defense mechanism of the human body and all living beings. However, being a tripeptide (γ‐glutamylcysteinylglycine), it poorly penetrates cells. L‐cysteine (L‐cys) is the rate‐limiting amino acid in GSH synthesis. NAC easily penetrates cells where it is deacetylated to yield L‐cys thereby promoting GSH synthesis. Therefore, NAC works per se in the extracellular environment and as a precursor of GSH inside cells. Accordingly, all its intracellular effects are mediated by GSH replenishment. Recycling of GSH increases but cannot match the high consumption in COVID‐19 lung disease. This requires new GSH synthesis, which increases enormously, largely through activation and up‐regulated production of glutamate‐cysteine ligase (GCL), the rate‐limiting enzyme for GSH biosynthesis that in turn depends on the availability of intracellular L‐cys, the rate‐limiting substrate for the enzyme. 13 NAC has better oral and topical bioavailability than GSH, and has an excellent safety profile. However, the systemic bioavailability of NAC after oral administration is relatively poor. 14 This thiol has been in clinical use since the 1960s as a mucolytic agent, usually at the oral dose of 600 mg, due to its ability to break the disulfide bonds of mucus and depolymerize mucin. As previously mentioned, breaking disulfide bonds into thiol groups may also reduce the affinity for the virus to attach to ACE2 sites. 9 NAC is also used in nebulized format in patients with acute bronchopulmonary disease, such as pneumonia, bronchitis, and tracheobronchitis. Moreover, NAC is quoted in the WHO Model List of Essential Medicines as an antidote in poisonings. At doses as high as 150 mg/kg intravenously, NAC is extensively used and is in standard practice as a clinically approved antidote against paracetamol (acetaminophen) intoxication, and it is almost 100% effective if given within 8 hours postingestion. 15 Paracetamol overdosage may cause mitochondrial oxidative imbalance and nitrosative stress leading to liver injury, which is the most common cause of acute liver failure in many countries. 16 The intravenous administration of NAC is also used to prevent contrast‐induced nephropathy that, again, is an inflammatory condition. 15

In addition, this pleiotropic drug has been proposed to attenuate the toxicity of various agents that cause the generation of free radicals as well as for the therapy and/or prevention of a variety of diseases involving GSH depletion and redox status alterations, such as heart diseases, diabetes, AIDS, neurodegenerative diseases, neuropsychiatric disorders, and several other conditions. 14 , 17


Oxidative stress and inflammation are strictly inter‐related. Exposure of cells either to the hydroxyl radical (•OH) or the superoxide radical anion (O2) induces a dose‐dependent release of pro‐inflammatory cytokines. Lipopolysaccharide (LPS) induces intracellular accumulation of reactive oxygen species (ROS) and augments the release of interleukin (IL)‐1beta, IL‐6, and tumor necrosis factor‐alpha (TNF‐α). A kappa B (κB‐α)/nuclear factor kappa B (NF‐κB)‐independent pathway mediates the redox‐dependent regulation of inflammatory cytokines, and this process is enhanced by GSH depletion. 18

ROS and thiol antioxidants, including GSH, regulate innate immunity at various levels, as documented by a broad literature. GSH is not only important as an antioxidant, but also as a signaling molecule in the redox‐sensitive steps of the cellular mechanisms implicated in inflammation and host defense against infection. 19 It is noteworthy that GSH not only affects certain factors involved in immunological processes, but it also modifies complex immune reactions such as fever, and there are data suggesting that fever induction is associated with oxidative stress. 20 Although the complement system is a key mediator of the innate immune response that protects against infectious agents, it also plays a critical role in promoting the inflammatory process that leads to tissue injury. 21 In particular, complement may be involved in coronavirus pathogenesis, as inferred from the finding that C3 knockout mice infected with SARS‐CoV have less lung disease than wild‐type mice. 22 Preliminary data provide evidence for activation of complement (sC5b‐9 and C5a) in patients with COVID‐19, with significantly higher plasma levels in the patients with severe disease than in those with moderate disease. Hence, complement activation has been suggested as a novel therapeutic target in COVID‐19. 21 In this context, it is noteworthy that administration of NAC (2 × 600 mg/day for 8 weeks) in a placebo‐controlled study has been shown to reduce the plasma levels of inflammatory markers, including complement (C3), in peritoneal dialysis patients. 23

Chronic oxidative stress, causing biomolecular damage, contributes to the age‐related decline in physiological functions, including the immune function. The daily administration of NAC (600 mg) to postmenopausal women strengthened the immune defenses thereby decreasing the probability of immune system‐related diseases in aging, such as infections, as shown by monitoring several lymphocyte functions (adherence, chemotaxis, proliferation, and natural killer activity) and neutrophil functions (adherence, chemotaxis, phagocytosis, and superoxide) as well as cytokine levels (IL‐2, IL‐8, and TNF‐α). 24


NAC works via a broad variety of mechanisms, which inside cells are mediated by GSH replenishment. A major one is its nucleophilicity, which consists of the ability of sulfhydryl groups (–SH) to react with electrophilic metabolites, either directly or via GSH S‐transferases. 17 This property results in binding of DNA reactive metabolites and in blocking reactive intermediates. An example of reactive intermediate is the paracetamol metabolite N‐acetyl‐p‐benzoquinone imine (NAPQI) formed via cytochrome P450 enzymes. In addition, NAC can exert antioxidant activity via p53‐mediated apoptosis. 25 L‐Cys, derived by NAC catabolism, is readily bioconverted to the vasodilator, anti‐inflammatory and readily diffusible hydrogen sulfide. Therefore, NAC should be regarded as a hydrogen sulfide donor. 26

Some major mechanisms responsible for the antioxidant/anti‐inflammatory properties of NAC are summarized in Figure Figure1.1. First of all, it has been established for a long time that NAC is a potent scavenger of ROS and especially of hypochlorous acid (HOCl) and •OH. 27 Inhibition by NAC of the ROS‐producing vascular NAD(P)H oxidases is relevant to prevention of hypertension and to pathological states associated with uncontrolled growth and inflammation, such as atherosclerosis. 28 The SH‐groups within the NAC molecule can also scavenge several reactive nitrogen species (RNS) that play a role in the oxidation of lipids, proteins, and DNA. 29 NAC potentiates the vasodilator and antiaggregatory effects of nitric oxide, which is a very important interaction clinically, and which has been shown to be valuable in the context of acute heart failure and acute myocardial ischemia and infarction. 30

Inhibition by NAC of epidermal growth factor receptor (EGFR), a tyrosine kinase involved in inflammation, 14 , 31 also results in a decreased inactivation of α1‐antitrypsin. In particular, NAC has the ability to improve the efficacy and structural conformational integrity of α1‐antitrypsin via a GSH‐mediated mechanism, and it enhances α1‐antitrypsin transcytosis thus improving its cellular uptake and functions. 32 In experimental studies, the oral administration of NAC to pregnant mice enhanced the expression of the gene encoding for an α1‐antitrypsin precursor in the fetal liver. 33 Together with redox imbalance, α1‐antitrypsin deficiency is involved in the pathogenesis of COPD. NAC was found to reduce IL‐8 levels, normalized C‐reactive protein (CRP) levels, and improved clinical outcomes in patients with COPD exacerbations. 34 A prospective, randomized, controlled trial in the Shandong Province, China enrolling adult bronchiectasis patients with at least two exacerbations in the previous year showed that oral NAC (600 mg twice daily for 12 months) was able to reduce the risk of exacerbations. 35

In addition, NAC has been shown to have protective effects in ARDS. It is well established that ROS play a key role in the pathogenesis of the acute lung injury and that the alveolar epithelial lining fluid of patients with ARDS is deficient in GSH, which may predispose these patients to that disease. 36 A randomized, double‐blind, placebo‐controlled, prospective clinical trial in 5 ICUs in the USA and Canada showed that the intravenous administration of NAC (70 mg/kg body weight), every 8 hours for 10 days, effectively repleted GSH in red blood cells, decreased the number of days of acute lung injury, and significantly increased the cardiac index. 37 NAC (50 mg/kg body weight in 250 mL of 5% dextrose for 6 days) protected the lungs of ARDS patients, as evaluated by measuring the expired ethane and malondialdehyde (MDA) as well as GSSG and GSH in the epithelial lining fluid. 38 In another study, patients hospitalized in ICU who received NAC (150 mg/kg body weight on the first day, followed by 50 mg/kg for 3 days) had a better clinical outcome as compared with patients in the placebo group. Moreover, NAC increased extracellular total antioxidant power and total thiol molecules. 39

A further mechanism is that NAC further enhances the stimulation of nuclear factor erythroid 2‐related factor 2 (Nrf2) by oxidative stress, 40 which favors transcription of phase II enzyme genes and downregulates inflammation. In fact, Nrf‐2 is essential for the antioxidant responsive element (ARE)‐mediated induction of endogenous antioxidant enzymes such as heme oxygenase 1 (HO‐1), NAD(P)H dehydrogenase [quinone] 1 (NQO‐1), and GCL. 41 Interestingly, it has been proposed that targeting the heme‐heme oxygenase system may prevent severe complications following COVID‐19 infection. 42 In parallel, NAC inhibits the oxidative stress‐mediated activation of nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NFκB) and biochemical pathways upregulating pro‐inflammatory genes. 14 NAC also reduced the intracellular hydrogen peroxide concentration and restored the intracellular total thiol contents by inhibiting NFκB translocation to the cellular nucleus and phosphorylation of p38 mitogen‐activated protein kinase (MAPK p38). 43 In influenza infection, NAC inhibits the induction of pro‐inflammatory cytokine response through endosomal toll‐like receptor 3/hemagglutinin (TLR3/HA)‐induced, ROS‐dependent NFκB activation. 44

Furthermore, NAC has anti‐inflammatory activity independently of its antioxidant activity, as shown by the finding that it inhibited the LPS‐mediated neurogenic inflammation by counteracting the release of Na,K‐ATPase (NKA), a marker for cell necrosis, which could explain the fall in IL‐6 with NAC. 45 A multicenter, randomized, placebo‐controlled trial, sequentially testing early use of intravenous NAC, followed by oral ramipril for 12 weeks, is based on the rationale that these agents have the ability to limit nitrosative stress and expression of the inflammasome activator thioredoxin interacting protein (TXNIP). 46


NAC has been demonstrated to attenuate the incidence and severity of influenza and influenza‐like illnesses. It was tested in a double‐blind trial, involving 20 Italian Centers, which enrolled 262 subjects of both sexes randomized to receive either placebo or NAC tablets (600 mg) twice daily for 6 months. Both local and systemic symptoms were sharply and significantly reduced in the NAC group. Moreover, only 25% of A/H1N1 influenza virus‐infected subjects under NAC treatment developed a symptomatic form vs 79% in the placebo group. 47

Infection by RNA viruses induces oxidative stress in host cells, and growing evidence indicates that viral replication is regulated by the redox state of the host cell and that the GSH content contributes to downregulate influenza virus replication. 48 An experimental study showed that GSH decreased the production of influenza virus particles in canine kidney cells or human small airway epithelial cells, where it inhibited the expression of viral matrix protein, caspase activation, and Fas upregulation. Moreover, administration of GSH with the drinking water to BALB/c mice decreased the viral titer in both lung and trachea 4 days after intranasal inoculation of the mouse‐adapted influenza strain A/X‐31. 49

It has also been demonstrated that NAC inhibits virus replication and expression of pro‐inflammatory molecules in adenocarcinoma human alveolar basal epithelial (A549) cells infected by the highly pathogenic H5N1 influenza virus. 50 NAC inhibited the pulmonary inflammation and edema as well as myeloperoxidase (MPO) activity, total cells, neutrophils, macrophages, TNF‐α, IL‐6, IL‐1β, and chemokine (C‐X‐C motif) ligand‐10 (CXCL‐10) in the bronchoalveolar lavage fluid and reduced the levels of toll‐like receptor 4 (TLR4) protein and mRNA in the lungs of BALB/c mice inoculated intranasally with A/swine/HeBei/012/2008/ H9N2 influenza virus. 51 A study in the same strain of mice showed that old animals had lower GSH concentrations than young animals in spleen, lymph nodes, lungs, and pancreas. The gene expression of endoplasmic reticulum stress markers involved in GSH metabolism and folding of proteins, such as Nrf2 and protein disulfide isomerase (PDI), was reduced in the lung of old mice. Treatment with the N‐butanoyl GSH derivative (GSH‐C4) of old mice infected with influenza A PR8/H1N1 virus increased GSH content in organs, reduced viral replication, and induced an immune response, in particular the Th1 (T helper‐1) cytokine profile. 52

Influenza A and B viruses and respiratory syncytial virus (RSV) are responsible for COPD by increasing inflammatory and apoptosis events through mechanisms involving ROS generation and release of mucins from epithelial cells. NAC inhibited the replication of these viruses and restored the normal functions of alveolar type II A549 cells by modulating MUC5AC overexpression and release and by inhibiting IL‐8, IL‐6, and TNF‐ α as well as NF‐κB translocation to the nucleus and phosphorylation of MAPK p38. 53

Furthermore, it has been known for almost 30 years that GSH plays an important defense role against HIV and that NAC may exert protective effects toward this viral infection. For instance, in agreement with data obtained in cells exposed to herpesvirus type 1 (DNA virus) or to Sendai (an RNA virus belonging to the family of Paramyxoviridae), it was shown that GSH inhibits HIV envelope glycoproteins (gp120) and interferes with late stages of virus replication in chronically infected macrophages, a known reservoir of the virus in the body. 54 Both GSH and NAC inhibited the induction of HIV‐1 expression in a chronically HIV‐1‐infected promonocytic cell line (U1/HIV) and in human primary monocyte/macrophages cultured in vitro, where both thiols decreased HIV‐1 p24 antigen levels as well as reverse transcriptase activity. 55

Interestingly, NAC appears to synergize with antivirals in the protection toward influenza in mouse models, as shown with ribavirin 56 and oseltamivir. 57


Smokers are more vulnerable to infectious diseases, as shown in the case of influenza and of the MERS‐CoV outbreak. An analysis of the literature suggests that smoking is most likely associated with the negative progression and adverse outcomes of COVID‐19. 58 Exposure to cigarette smoke increases ROS levels and causes a drop in GSH intracellular concentrations. 59 Aldehydes in cigarette smoke deplete the total available GSH pool by reacting to form nonreducible GSH‐aldehydes derivatives. 60 GSH depletion accelerates cigarette smoke‐induced inflammation and airspace enlargement, and the GSH adaptive response declines with age. 61

By increasing GSH production, NAC has the ability to modulate a large variety of smoking‐related end‐points and cancer in experimental test systems, due to many interconnected mechanisms and properties. 17 , 62 In addition, NAC was shown to attenuate several biomarker alterations in a randomized, double‐blind, placebo‐controlled, Phase II chemoprevention trial in heavy smokers who received NAC tablets (600 mg) twice daily for 6 months. 63


NAC is approved by FDA under various formulations and is popular as a health supplement, this molecule having been proposed as a nutraceutical that might aid the control of RNA viruses including influenza and coronavirus. 64 , 65 , 66 Almost 60 years of experience in the prophylaxis and therapy of a variety of clinical conditions have established the safety of this drug, even at very high doses and for long‐term treatments. Drug repurposing is the fastest strategy toward an effective and accessible treatment against COVID‐19 before a vaccine is available, 67 and molecules working via multiple mechanisms of action, such as NAC, are more likely to be effective as compared with drugs having a single target.

Based on the herein discussed mechanistic premises, NAC may be proposed both in the prevention and in the therapy of COVID‐19. In particular, the oral administration of NAC, at the dose of 600 mg twice daily, may be proposed for preventive purposes aimed at attenuating the risk of developing COVID‐19 and its severity during epidemic periods, as we previously demonstrated in the case of influenza and influenza‐like illnesses, 47 especially in elderly people and in individuals who suffer from chronic conditions that predispose them to this kind of diseases and increase their severity. Persons who have been in proximity of infected SARS‐CoV‐2 carriers, including those detected by means of smartphone contact tracing apps, may be an additional target for taking oral NAC in order to decrease the risk of developing COVID‐19.

In addition, NAC has been shown to exert protective mechanisms against a variety of conditions associated with COVID‐19 and co‐morbidities thereof, also including cardiovascular diseases. 16 Given that cardiac injury and thrombosis are well established as potentially lethal complications in COVID‐19, it is noteworthy that intravenously administered NAC has been shown to potentiate the vasodilator, anti‐inflammatory and antiaggregatory effects of nitroglycerin, and this useful interaction has been translated into improving outcomes, such as in acute myocardial infarction, unstable angina and acute pulmonary edema. 68 , 69 Administration of NAC has been included among the possible strategies aimed at preserving endothelial function and limiting microthrombosis in severe forms of COVID‐19. 70

In case of severe COVID‐19 forms with pulmonary and/or systemic symptoms, intravenously administered NAC at the high doses that are commonly used in case of paracetamol intoxication, given at the first onset of chest symptoms, would be expected to play an adjuvant therapeutic role in combination with antivirals or other drugs. A potential role of NAC and copper in combination with candidate antiviral treatments against SARS‐CoV‐2, such as remdesivir, has been hypothesized based on a systematic literature search. 71 Clearly, the potential anti‐COVID‐19 mechanisms and properties of this thiol have to be substantiated in controlled clinical trials, some of which are now in progress. 12 , 72


The authors declare no conflicts of interest to disclose.


S. De Flora conceived and researched the hypothesis proposed in this manuscript and wrote the manuscript. R. Balansky and S. La Maestra critically reviewed the manuscript and contributed to the hypothesis exploration. All authors read and approved the published version of the manuscript.


De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. The FASEB Journal. 2020;00:1–9. 10.1096/fj.202001807 [PMC free article] [PubMed] [CrossRef] [Google Scholar]


1. Cao X. COVID‐19: immunopathology and its implications for therapy. Nature Rev Immunol. 2020. 10.1038/s41577-020-0308-3. [Epub ahead of print]. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID‐19. J Pharm Anal. 2020. 10.1016/j.jpha.2020.03.001. [Epub ahead of print]. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. A current review of COVID‐19 for the cardiovascular specialist [published online ahead of print, 2020 May 3]. Am Heart J. 2020;226:29‐44. 10.1016/j.ahj.2020.04.025. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Istituto Superiore di Sanità. Epicentro . Characteristics of SARS‐CoV‐2 patients dying in Italy. Report based on available data on May 28th, 2020. https://www.epicentro.iss.it/en/coronavirus/sars‐cov‐2‐analysis‐of‐death
5. Wang L, Ahn YJ, Asmis R. Sexual dimorphism in glutathione metabolism and glutathione‐dependent responses. Redox Biol. 2019;17:101410 10.1016/j.redox.2019.101410. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Nasi A, McArdle S, Gaudernack G, et al. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS‐CoV‐2 in an ageing population, consider N‐acetylcysteine as early therapeutic intervention. Toxicol Rep. 2020;7:768‐771. 10.1016/j.toxrep.2020.06.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Cao M, Zhang D, Wang Y, et al. Clinical features of patients infected with the 2019 novel coronavirus (COVID‐19) in Shanghai, China. Preprint. medRxiv. 2020. 10.1101/2020.03.04.20030395. [CrossRef] [Google Scholar]
8. Polonikov AV. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death from novel coronavirus infection(COVID‐19): a hypothesis based on literature data and own observations. ACS Infect Dis. 2020: acsinfecdis.0c00288. Published online 2020 May 28. 10.1021/acsinfecdis.0c00288. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Hoffmann M, Kleine‐Weber H, Schroeder S, et al. SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8. 10.1016/j.cell.2020.02.052. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Hati S, Bhattacharyya S. Impact of thiol‐disulfide balance on the binding of Covid‐19 spike protein with angiotensin converting enzyme 2 receptor. bioRxiv preprint 2020. 10.1101/2020.05.07.083147. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Boesgaard S, Aldershvile J, Poulsen HE, Christensen S, Dige‐Petersen H, Giese J. N‐acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exp Ther. 1993;265(3):1239‐1244. [PubMed] [Google Scholar]
12. Jorge‐Aarón RM, Rosa‐Ester MP. N‐acetylcysteine as a potential treatment for novel coronavirus disease 2019 [published online ahead of print, 2020 Jul 14]. Future Microbiol. 2020. 10.2217/fmb-2020-0074. [CrossRef] [Google Scholar]
13. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30:42‐59. 10.1016/j.mam.2008.05.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. Sadowska AM. N‐Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2012;6:127‐135. 10.1177/1753465812437563. [PubMed] [CrossRef] [Google Scholar]
15. Ershad M, Wermuth HR, Vearrier D. N Acetylcysteine In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. [Google Scholar]
16. Šalamon Š, Kramar B, Marolt TP, Poljšak B, Milisav I. Medical and dietary uses of N‐acetylcysteine. Antioxidants (Basel). 2019;8:pii: E111 10.3390/antiox8050111. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. De Flora S, Izzotti A, D'Agostini F, Balansky RM, Balansky RM. Mechanisms of N‐acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking‐related end‐points. Carcinogenesis. 2001;22:999‐1013. [PubMed] [Google Scholar]
18. Haddad JJ. Glutathione depletion is associated with augmenting a proinflammatory signal: evidence for an antioxidant/pro‐oxidant mechanism regulating cytokines in the alveolar epithelium. Cytokines Cell Mol Ther. 2000;6:177‐187. [PubMed] [Google Scholar]
19. Ghezzi P. Role of glutathione in immunity and inflammation in the lung. Int J Gen Med. 2011;4:105‐113. 10.2147/IJGM.S15618. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Wrotek S, Sobocińska J, Kozłowski HM, Pawlikowska M, Jędrzejewski T, Dzialuk A. New insights into the role of glutathione in the mechanism of fever. Int J Mol Sci. 2020;21:pii: E1393 10.3390/ijms21041393. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Maglakelidze N, Manto KM, Craig TJ A review: Does complement or the contact system have a role in protection or pathogenesis of COVID‐19? Pulm Ther. 2020:1‐8. 10.1007/s41030-020-00118-5. Online ahead of print. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Cugno M, Meroni PL, Gualtierotti R, et al. Complement activation in patients with COVID‐19: A novel therapeutic target. J Allergy Clin Immunol. 2020;14:S0091‐6749(20)30650‐3. 10.1016/j.jaci.2020.05.006. Online ahead of print. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Purwanto B, Prasetyo DH. Effect of oral N‐acetylcysteine treatment on immune system in continuous ambulatory peritoneal dialysis patients. Acta Med Indones. 2020;44:140‐144. [PubMed] [Google Scholar]
24. Arranz L, Fernandez C, Rodriguez A, Ribera J, Delafuente M. The glutathione precursor N‐acetylcysteine improves immune function in postmenopausal women. Free Radic Biol Med. 2008;45:1252‐1262. 10.1016/j.freeradbiomed.2008.07.014. [PubMed] [CrossRef] [Google Scholar]
25. Liu M, Pelling JC, Ju J, Chu E, Brash DE. Antioxidant action via p53‐mediated apoptosis. Cancer Res. 1998;58:1723‐1729. [PubMed] [Google Scholar]
26. Aldini G, Altomare A, Baron G, et al. N‐Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52:751‐762. 10.1080/10715762.2018.1468564. [PubMed] [CrossRef] [Google Scholar]
27. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N‐acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989;6:593‐597. 10.1016/0891-5849(89)90066-x. [PubMed] [CrossRef] [Google Scholar]
28. Griendling KK, Sorescu D, Ushio‐Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494‐501. 10.1161/01.res.86.5.494. [PubMed] [CrossRef] [Google Scholar]
29. Tardiolo G, Bramanti P, Mazzon E. Overview on the effects of N‐acetylcysteine in neurodegenerative diseases. Molecules. 2018;23:pii: E3305. 10.3390/molecules23123305. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001;88:756‐762. 10.1161/hh0801.089861. [PubMed] [CrossRef] [Google Scholar]
31. Lee M‐F, Chan C‐Y, Hung H‐C, Chou I‐T, Yee AS, Huang C‐Y. N‐acetylcysteine (NAC) inhibits cell growth by mediating the EGFR/Akt/HMG box‐containing protein 1 (HBP1) signaling pathway in invasive oral cancer. Oral Oncol. 2013;49:129‐135. 10.1016/j.oraloncology.2012.08.003. [PubMed] [CrossRef] [Google Scholar]
32. Patel K, Cheng G, Rucker L, Bazzle G, Nadig S, Atkinson C. N‐acetylcysteine potentiates the protective effects of α‐1‐antitrypsin in a mouse model of orthotopic lung transplantation. J Heart Lung Transpl. 2017;36:S371. [Google Scholar]
33. Izzotti A, Balansky R, Cartiglia C, Camoirano A, Longobardi M, De Flora S. Genomic and transcriptional alterations in mouse fetus liver after transplacental exposure to cigarette smoke. FASEB J. 2003;17:1127‐1129. [PubMed] [Google Scholar]
34. Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M. High‐dose N‐acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Cl Drug Invest. 2005;25:401‐408. [PubMed] [Google Scholar]
35. Qi Q, Ailiyaer Y, Liu R, et al. Effect of N‐acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir Res. 2019;20:73 10.1186/s12931-019-1042-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
36. Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest. 1991;100:1397‐1403. [PubMed] [Google Scholar]
37. Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N‐acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997;112:164‐172. [PubMed] [Google Scholar]
38. Ortolani O, Conti A, De Gaudio AR, Masoni M, Novelli G. Protective effects of N‐acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock. 2000;13:14‐18. [PubMed] [Google Scholar]
39. Soltan‐Sharifi MS, Mojtahedzadeh M, Najafi A, et al. Improvement by N‐acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti‐oxidant power: evidence for underlying toxicological mechanisms. Human Exp Toxicol. 2007;26:697‐703. [PubMed] [Google Scholar]
40. Zhou Y, Wang HD, Zhou XM, Fang J, Zhu L, Ding K. N‐acetylcysteine amide provides neuroprotection via Nrf2‐ARE pathway in a mouse model of traumatic brain injury. Drug Des Devel Ther. 2018;2018(12):4117‐4127. 10.2147/DDDT.S179227. eCollection 2018. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
41. Zhao N, Guo FF, Xie KQ, Zeng T. Targeting Nrf‐2 is a promising intervention approach for the prevention of ethanol‐induced liver disease. Cell Mol Life Sci. 2018;75:3143‐3157. 10.1007/s00018-018-2852-6. [PubMed] [CrossRef] [Google Scholar]
42. Wagener FADTG, Pickkers P, Peterson SJ, Immenschuh S, Abraham NG. Targeting the heme‐heme oxygenase system to prevent severe complications following COVID‐19 infections. Antioxidants (Basel). 2020;9:E540 Published 2020 Jun 19. 10.3390/antiox9060540. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Hui DSC, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses. 2013;7(Suppl 3):52‐59. 10.1111/irv.12171. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
44. Lai KY, Wing Yiu GNG, Cheng FF. The W‐shaped mortality‐age distribution of novel H1N1 influenza virus helps reconstruct the second wave of pandemic 1918 Spanish flu. J Pulm Respir Med. 2015;5:245 10.4172/2161-105X.1000245. [CrossRef] [Google Scholar]
45. Calzetta L, Matera MG, Rogliani P, Cazzola M. Multifaceted activity of N‐acetyl‐l‐cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018;12:693‐708. 10.1080/17476348.2018.1495562. [PubMed] [CrossRef] [Google Scholar]
46. Ong GJ, Nguyen TH, Stansborough J, et al. The N‐AcetylCysteine and RAMipril in Takotsubo Syndrome Trial (NACRAM): Rationale and design of a randomised controlled trial of sequential N‐Acetylcysteine and ramipril for the management of Takotsubo Syndrome. Contemp Clin Trials. 2020;90:105894 10.1016/j.cct.2019.105894. [PubMed] [CrossRef] [Google Scholar]
47. De Flora S, Grassi C, Carati L. Attenuation of influenza‐like symptomatology and improvement of cell‐mediated immunity with long‐term N‐acetylcysteine treatment. Eur Respir J. 1997;10:1535‐1541. [PubMed] [Google Scholar]
48. Nencioni L, Iuvara A, Aquilano K, et al. Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl‐2. FASEB J. 2003;17:758‐760. [PubMed] [Google Scholar]
49. Cai J, Chen Y, Seth S, Furukawa S, Compans RW, Jones DP. Inhibition of influenza infection by glutathione. Free Radic Biol Med. 2003;34:928‐936. [PubMed] [Google Scholar]
50. Geiler J, Michaelis M, Naczk P, et al. N‐acetyl‐L‐cysteine (NAC) inhibits virus replication and expression of pro‐inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Bioch Pharmacol. 2010;79:413‐420. [PubMed] [Google Scholar]
51. Zhang R‐H, Li C‐H, Wang C‐L, et al. N‐acetyl‐l‐cystine (NAC) protects against H9N2 swine influenza virus‐induced acute lung injury. Int Immunopharmacol. 2014;22:1‐8. 10.1016/j.intimp.2014.06.013. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Amatore D, Celestino I, Brundu S, et al. Glutathione increase by the n‐butanoyl glutathione derivative (GSH‐C4) inhibits viral replication and induces a predominant Th1 immune profile in old mice infected with influenza virus. FASEB Bioadv. 2019;1:296‐305. 10.1096/fba.2018-00066. eCollection 2019 May. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
53. Mata M, Morcillo E, Gimeno C, Cortijo J. N‐acetyl‐L‐cysteine (NAC) inhibit mucin synthesis and pro‐inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Bioch Pharmacol. 2011;82:548‐555. 10.1016/j.bcp.2011.05.014. [PubMed] [CrossRef] [Google Scholar]
54. Palamara AT, Perno CF, Aquaro S, Buè MC, Dini L, Garaci E. Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. AIDS Res Hum Retroviruses. 1996;12:1537‐1541. [PubMed] [Google Scholar]
55. Ho WZ, Douglas SD. Glutathione and N‐acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro. AIDS Res Hum. Retroviruses. 1992;8:1249‐1253. [PubMed] [Google Scholar]
56. Ghezzi P, Ungheri D. Synergistic combination of N‐acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol. 2004;17:99‐102. [PubMed] [Google Scholar]
57. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. N‐acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol. 2007;20:349‐354. [PubMed] [Google Scholar]
58. Vardavas CI, Nikitara K. COVID‐19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:20 10.18332/tid/119324. eCollection 2020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
59. Bazzini C, Rossetti V, Civello DA, et al. Short‐ and long‐ term effects of cigarette smoke exposure on glutathione homeostasis in human bronchial epithelial cells. Cell Physiol Biochem. 2013;32:129‐145. 10.1159/000356633. [PubMed] [CrossRef] [Google Scholar]
60. van der Toorn M, Smit‐de Vries MP, Slebos D‐J, et al. Cigarette smoke irreversibly modifies glutathione in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1156‐L1162. [PubMed] [Google Scholar]
61. Gould NS, Min E, Huang J, et al. Glutathione depletion accelerates cigarette smoke‐induced inflammation and airspace enlargement. Toxicol Sci. 2015;147:466‐474. 10.1093/toxsci/kfv143. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
62. Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S. Prevention of cigarette smoke‐induced lung tumors in mice by budesonide, phenethyl isothiocyanate and N‐acetylcysteine. Int J Cancer. 2010;126:1047‐1054. 10.1002/ijc.24942. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Van Schooten FJ, Besaratinia A, De Flora S, et al. Effects of oral administration of N‐acetyl‐L‐cysteine: a multi‐biomarker study in smokers. Cancer Epidemiol Biom Prev. 2002;11:167‐175. [PubMed] [Google Scholar]
64. McCarty MF, DiNicolantonio JJ. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus. Prog Cardiovasc Dis. 2020. pii: S0033–0620(20)30037–2. 10.1016/j.pcad.2020.02.007. [Epub ahead of print]. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
65. Bauer SR, Kapoor A, Rath M, Thomas SA. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N‐acetylcysteine for prevention or treatment of COVID‐19? Cleve Clin J Med. 2020. 10.3949/ccjm.87a.ccc046. Online ahead of print. [PubMed] [CrossRef] [Google Scholar]
66. DiNicolantonio JJ, Barroso‐Aranda J. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID‐19: Potential of pentoxifylline and dipyridamole. Med Hypotheses. [published online ahead of print, 2020 Jul 2]. [PMC free article] [PubMed] [Google Scholar]
67. Fajgenbaum DC, Khor JS, Gorzewski A, et al. Treatments administered to the first 9152 reported cases of COVID‐19: A systematic review. Infect Dis Ther. 2020;9:1‐15. 10.1007/s40121-020-00303-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
68. Marchetti G, Lodola E, Licciardello L, Colombo A. Use of N‐acetylcysteine in the management of coronary artery diseases. Cardiologia. 1999;44:633‐637. [PubMed] [Google Scholar]
69. Pasupathy S, Tavella R, Grover S, et al. Early use of N‐acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST‐segment‐elevation myocardial infarction reduces myocardial infarct size (the NACIAM Trial [N‐acetylcysteine in Acute Myocardial Infarction]). Circulation. 2017;136:894‐903. 10.1161/CIRCULATIONAHA.117.027575. [PubMed] [CrossRef] [Google Scholar]
70. Guglielmetti G, Quaglia M, Sainaghi PP, et al. “War to the knife” against thromboinflammation to protect endothelial function of COVID‐19 patients. Crit Care. 2020;24:365 Published 2020 Jun 19. 10.1186/s13054-020-03060-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
71. Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. COVID‐19: the potential role of copper and N‐acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS‐CoV‐2. In Vivo. 2020;34(3 Suppl):1567‐1588. 10.21873/invivo.11946.1007/s40121-020-00303-8. [Epub ahead of print]. [PubMed] [CrossRef] [Google Scholar]
72. Poe FL, Corn J. N‐Acetylcysteine: a potential therapeutic agent for SARS‐CoV‐2. Med Hypotheses. 2020;143:109862 10.1016/j.mehy.2020.109862. [published online ahead of print, 2020 May 30]. [PMC free article] [PubMed] [CrossRef] [Google Scholar]